Dr. Omar Nadeem completed his internal medicine residency training at Dartmouth–Hitchcock Medical Center and his hematology/oncology fellowship at the Warren Alpert Medical School of Brown University. He joined the Jerome Lipper Multiple Myeloma Center at Dana–Farber Cancer Institute in 2018, where he is a Senior Physician and serves as the Clinical Director of the Myeloma Immune Effector Cell Therapy Program and as the Medical Director of the Center for Early Detection and Interception of Blood Cancers. He is an Assistant Professor of Medicine at Harvard Medical School and an Associate Director of the Myeloma Clinical Research Program. He serves as a principal investigator on several clinical trials ranging from precursor plasma cell disorders to relapsed and refractory multiple myeloma. His research interests include MGUS and smoldering myeloma and immunotherapy in the management of multiple myeloma.

Dr. Sikander Ailawadhi is an oncologist working in the Hematology Department and CAR T Cell Therapy Program at the Mayo Clinic based in Jacksonville, FL, USA. He obtained his medical degree from the University College of Medical Sciences and Guru Teg Bahadur Hospital, University of Delhi, in 2000. He completed his residency in Medical Microbiology at University College of Medical Sciences, University of Delhi, in 2003 and then proceeded to complete his residency in Internal Medicine at State University of New York, Buffalo, in 2006. He was also a Fellow in Medical Oncology at Roswell Park Cancer Institute, State University of New York, Buffalo, in 2008. Dr. Ailawadhi’s research interests include multiple myeloma, Waldenstrom’s macroglobulinemia, chronic leukemias (chronic lymphocytic leukemia; CLL, chronic myeloid leukemia; CML), clinical drug development in multiple myeloma and Waldenstrom’s macroglobulinemia, healthcare disparities and outcomes, cancer disparities among ethnic minorities, and biological variability in plasma cell dyscrasia.

Dr. Jack Khouri is an Associate Staff Member in Hematology and Medical Oncology at Cleveland Clinic Taussig Cancer Center and an Assistant Professor at Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. He is a clinician in the myeloma program, blood and marrow transplant program, and section of apheresis medicine. In his current role, Dr. Khouri cares for patients with PCDs in the outpatient setting and attends to the lymphoma/myeloma and bone marrow transplant inpatient services. He also oversees various procedures in the cancer center’s apheresis unit ranging from leukapheresis for mononuclear cell collections for HCT and CAR T cell therapy to inpatient and outpatient plasma exchange and photopheresis procedures for a variety of medical conditions across multiple medical specialties. He also has an interest in the role of apheresis procedures in myeloma and PCDs and is currently working on designing a phase 2 study of plasma exchange in cast nephropathy. Dr. Khouri has a special interest in POEMS syndrome and has created several PCD clinical pathways for our myeloma program namely for POEMS syndrome, MGUS, MGRS, and smoldering myeloma.

Dr. Louis Williams is a hematologist in the Department of Hematology and Medical Oncology, primarily at the Cleveland Clinic Main Campus in New York. He received his medical degree from Albany Medical College and has been in practice for over 6 years. He specializes in diagnosing, treating, and managing diseases originating in the blood, bone marrow, and lymph.

Donna Catamero is an Associate Director at Mount Sinai Hospital. She received a Bachelor of Science in Nursing from Simmons College in 2002 and her Master of Science in Nursing from New York University in 2010. For 20 years, she has been involved in clinical research. She worked as a nurse practitioner in the multiple myeloma program at New York University Langone Medical Center in New York City and later at Mount Sinai, also in New York City, until 2018. Then, Catamero spent two years in the industry working for Celgene Corporation as Scientific Director of Medical Affairs in multiple myeloma, where she supported the launch of ide-cel and developed a CAR T educational program for healthcare providers. She is now back at Mount Sinai, where she serves as Associate Director of Myeloma Research.

Dr. Kathryn Maples is a Clinical Pharmacy Specialist in multiple myeloma at the Winship Cancer Institute of Emory University in Atlanta, GA, USA. She obtained her Doctor of Pharmacy degree magna cum laude from the University of Georgia College of Pharmacy and then completed her PGY1 acute care and PGY2 oncology residencies at VCU Health before becoming a clinical specialist in 2017. Dr Maples’s research focuses on multiple myeloma treatments, allogeneic hematopoietic stem cell transplantation, and other hematologic malignancies, such as mantle cell lymphoma and leukemias.

Jesús Berdeja, MD, is an oncologist at Tennessee Oncology, Nashville, TN, USA. He graduated from the Medical School of Harvard University. He is on a residency at the University of California, San Francisco. He obtained a Fellowship at Johns Hopkins University School of Medicine, Baltimore. He has Board Certifications in Medical Oncology and Hematology. He is a Professional Member of ASH.